Doxazosin oral therapeutic system in a patient with arterial hypertension Review article
Article Sidebar
Published:
Mar 31, 2023
Keywords:
doxazosin, α-blockers, hypertension
Main Article Content
Abstract
In recent years, the effective therapy for patients with metabolic syndrome, which is a major risk factor for cardiovascular diseases, has become a serious challenge. Doxazosin – a selective α-adrenergic receptor antagonist, has emerged as a promising research target in the context of metabolic syndrome. A new extended-release gastrointestinal therapeutic system formulation of doxazosin was developed to improve the pharmacokinetic profile of the parent compound and to reduce or eliminate the need for dose titration and the potential risk of overdosing. According to current guidelines, doxazosin has an important position in the treatment of resistant hypertension.
Article Details
How to Cite
Postuła , M. (2023). Doxazosin oral therapeutic system in a patient with arterial hypertension. Medycyna Faktow (J EBM), 16(1(58), 107-110. https://doi.org/10.24292/01.MF.0123.19
Issue
Section
Articles
Copyright © by Medical Education. All rights reserved.
References
1. Cubeddu LX, Fuenmayor N, Caplan N et al. Clinical pharmacology of doxazosin in patients with essential hypertension. Clin Pharmacol Ther. 1987; 41(4): 439-49.
2. Fulton B, Wagstaff A, Sorkin E. Doxazosin. An update of its clinical pharmacology and therapeutic applications in hypertension and benign prostatic hyperplasia. Drugs. 1995; 49: 295-320.
3. Chung M, Vashi V, Puente J et al. Clinical pharmacokinetics of doxazosin in a controlled-release gastrointestinal therapeutic system (GITS) formulation. Br J Clin Pharmacol. 1999; 48: 678-87.
4. Andersson PE, Johansson J, Berne C et al. Effects of selective alfa 1 and beta 1-adrenoreceptor blockade on lipoprotein and carbohydrate metabolism in hypertensive subjects, with special emphasis on insulin sensitivity. J Hum Hypertens. 1994; 8: 219-26.
5. Kageyama S, Yamamoto J, Mimura A et al. Doxazosin improves insulin sensitivity in hypertensive patients. Clin Ther. 1993; 15: 829-37.
6. Lehtonen A. Doxazosin effects on insulin and glucose in hypertensive patients. Am Heart J. 1991; 121: 1307-11.
7. Inukai T, Inukai Y, Matsutomo R et al. Clinical usefulness of doxazosin in patients with type 2 diabetes complicated by hypertension: effects on glucose and lipid metabolism. J Int Med Res. 2004; 32: 206-13.
8. D’Eletto RD, Javitt NB. Effect of doxazosin on cholesterol synthesis in cell culture. J Cardiovasc Pharmacol. 1989; 13(suppl 2): S1-4; discussion S4.
9. Weinberger MH. Antihypertensive therapy and lipids: Paradoxical influences on cardiovascular disease risk. Am J Med. 1986; 80(2A): 64-70. http://doi.org/10.1016/0002-9343(86)90162-2.
10. Ferrara LA, Di Marino L, Russo O et al. Doxazosin and captopril in mildly hypercholesterolemic hypertensive patients. The Doxazosin-Captopril in Hypercholesterolemic Hypertensives Study. Hypertension. 1993; 21: 97-104.
11. Jansen H, Lammers R, Baggen MG et al. Effects of doxazosin on lipids, lipoprotein lipases, and cholesterol synthesis in the golden hamster. J Cardiovasc Pharmacol. 1989; 13(suppl 2): S-9; discussion S9-10.
12. Meredith PA, Elliott HL, Kelman AW et al. Pharmacokinetic and pharmacodynamic modelling of the alpha adrenoceptor antagonist doxazosin. Xenobiotica. 1988; 123-9. http://doi.org/10.3109/00498258809055143.
13. Ceral J, Solar M. Doxazosin: safety and efficacy in the treatment of resistant arterial hypertension. Blood Press. 2009; 18: 74-7.
14. Wykretowicz A, Guzik P, Wysocki H. Doxazosin in the current treatment of hypertension. Expert Opin Pharmacother. 2008; 9: 625-33.
15. Iii KPS, Suplement KP III. Wytyczne ESH/ESC dotyczące postępowania w nadciśnieniu tętniczym w 2013 roku. Kardiol Pol. 2013: 27-118. http://doi.org/10.5603/kp.2013.0177.
16. Os I, Stokke HP. Effects of doxazosin in the gastrointestinal therapeutic system formulation versus doxazosin standard and placebo in mild-t-moderate hypertension. Doxazosin Investigators’ Study Group. J Cardiovasc Pharmacol. 1999; 33: 791-7.
17. Os I, Stokke HP. Doxazosin GITS compared with doxazosin standard and placebo in patients with mild hypertension. Blood Press. 1999; 8: 184-91.
18. Lund-Johansen P, Kirby RS. Effect of doxazosin GITS on blood pressure in hypertensive and normotensive patients: a review of hypertension and BPH studies. Blood Press Suppl. 2003; 1: 5-13.
19. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). ALLHAT Collaborative Research Group. JAMA. 2000; 283: 1967-7.
2. Fulton B, Wagstaff A, Sorkin E. Doxazosin. An update of its clinical pharmacology and therapeutic applications in hypertension and benign prostatic hyperplasia. Drugs. 1995; 49: 295-320.
3. Chung M, Vashi V, Puente J et al. Clinical pharmacokinetics of doxazosin in a controlled-release gastrointestinal therapeutic system (GITS) formulation. Br J Clin Pharmacol. 1999; 48: 678-87.
4. Andersson PE, Johansson J, Berne C et al. Effects of selective alfa 1 and beta 1-adrenoreceptor blockade on lipoprotein and carbohydrate metabolism in hypertensive subjects, with special emphasis on insulin sensitivity. J Hum Hypertens. 1994; 8: 219-26.
5. Kageyama S, Yamamoto J, Mimura A et al. Doxazosin improves insulin sensitivity in hypertensive patients. Clin Ther. 1993; 15: 829-37.
6. Lehtonen A. Doxazosin effects on insulin and glucose in hypertensive patients. Am Heart J. 1991; 121: 1307-11.
7. Inukai T, Inukai Y, Matsutomo R et al. Clinical usefulness of doxazosin in patients with type 2 diabetes complicated by hypertension: effects on glucose and lipid metabolism. J Int Med Res. 2004; 32: 206-13.
8. D’Eletto RD, Javitt NB. Effect of doxazosin on cholesterol synthesis in cell culture. J Cardiovasc Pharmacol. 1989; 13(suppl 2): S1-4; discussion S4.
9. Weinberger MH. Antihypertensive therapy and lipids: Paradoxical influences on cardiovascular disease risk. Am J Med. 1986; 80(2A): 64-70. http://doi.org/10.1016/0002-9343(86)90162-2.
10. Ferrara LA, Di Marino L, Russo O et al. Doxazosin and captopril in mildly hypercholesterolemic hypertensive patients. The Doxazosin-Captopril in Hypercholesterolemic Hypertensives Study. Hypertension. 1993; 21: 97-104.
11. Jansen H, Lammers R, Baggen MG et al. Effects of doxazosin on lipids, lipoprotein lipases, and cholesterol synthesis in the golden hamster. J Cardiovasc Pharmacol. 1989; 13(suppl 2): S-9; discussion S9-10.
12. Meredith PA, Elliott HL, Kelman AW et al. Pharmacokinetic and pharmacodynamic modelling of the alpha adrenoceptor antagonist doxazosin. Xenobiotica. 1988; 123-9. http://doi.org/10.3109/00498258809055143.
13. Ceral J, Solar M. Doxazosin: safety and efficacy in the treatment of resistant arterial hypertension. Blood Press. 2009; 18: 74-7.
14. Wykretowicz A, Guzik P, Wysocki H. Doxazosin in the current treatment of hypertension. Expert Opin Pharmacother. 2008; 9: 625-33.
15. Iii KPS, Suplement KP III. Wytyczne ESH/ESC dotyczące postępowania w nadciśnieniu tętniczym w 2013 roku. Kardiol Pol. 2013: 27-118. http://doi.org/10.5603/kp.2013.0177.
16. Os I, Stokke HP. Effects of doxazosin in the gastrointestinal therapeutic system formulation versus doxazosin standard and placebo in mild-t-moderate hypertension. Doxazosin Investigators’ Study Group. J Cardiovasc Pharmacol. 1999; 33: 791-7.
17. Os I, Stokke HP. Doxazosin GITS compared with doxazosin standard and placebo in patients with mild hypertension. Blood Press. 1999; 8: 184-91.
18. Lund-Johansen P, Kirby RS. Effect of doxazosin GITS on blood pressure in hypertensive and normotensive patients: a review of hypertension and BPH studies. Blood Press Suppl. 2003; 1: 5-13.
19. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). ALLHAT Collaborative Research Group. JAMA. 2000; 283: 1967-7.